Vitamin K status in cystic fibrosis

Acta Paediatr. 1992 Sep;81(9):658-61. doi: 10.1111/j.1651-2227.1992.tb12327.x.


Appearance of PIVKA-II (protein induced by vitamin K absence-II) in serum is a biochemical sign of insufficient vitamin K-dependent carboxylation of prothrombin. Plasma concentrations of PIVKA-II and vitamin K1 were determined in 24 children with cystic fibrosis. Eight were supplemented with vitamin K1. The purpose of the study was to determine the occurrence of vitamin K deficiency in cystic fibrosis and to evaluate the effect of vitamin K supplementation. PIVKA-II was detectable in only one unsupplemented child. In this patient, the concentration of vitamin K1 was below the limit of detection of 60 ng/l. Vitamin K1 levels in the other unsupplemented children were normal (mean 476 ng/l = 1 mmol/l). The supplemented patients showed extremely high levels of vitamin K1 (mean 22445 ng/l = 50 nmol/l). In conclusion, vitamin K deficiency occurs infrequently in cystic fibrosis. Checking the coagulation system is advised, but routine vitamin K supplementation is not recommended. If additional vitamin K is needed, the starting dose should not exceed 1 mg daily.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Child
  • Child, Preschool
  • Cystic Fibrosis / blood
  • Cystic Fibrosis / complications*
  • Decarboxylation
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Protein S / analysis
  • Prothrombin / analysis
  • Vitamin K / therapeutic use
  • Vitamin K Deficiency / complications*
  • Vitamin K Deficiency / prevention & control


  • Protein S
  • Vitamin K
  • Prothrombin